Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

Wei Wang, a UH College of Pharmacy research associate professor, is helping to develop a new targeted drug to treat triple-negative breast cancer. Photo courtesy UH.

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”

From Your Site Articles
Coya Therapeutics plans to scale up manufacturing and prepare for the commercialization of COYA 302, its ALS therapy drug. Photo via Getty Images

Houston biotech co. raises $11M to advance ALS drug development

drug money

Houston-based clinical-stage biotechnology company Coya Therapeutics (NASDAQ: COYA) has raised $11.1 million in a private investment round.

India-based pharmaceuticals company Dr. Reddy’s Laboratories Inc. led the round with a $10 million investment, according to a news release. New York-based investment firm Greenlight Capital, Coya’s largest institutional shareholder, contributed $1.1 million.

The funding was raised through a definitive securities purchase agreement for the purchase and sale of more than 2.5 million shares of Coya's common stock in a private placement at $4.40 per share.

Coya reports that it plans to use the proceeds to scale up manufacturing of low-dose interleukin-2 (IL-2), which is a component of its COYA 302 and will support the commercial readiness of the drug. COYA 302 enhances anti-inflammatory T cell function and suppresses harmful immune activity for treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease.

The company received FDA acceptance for its investigational new drug application for COYA 302 for treating ALS and FTD this summer. Its ALSTARS Phase 2 clinical trial for ALS treatment launched this fall in the U.S. and Canada and has begun enrolling and dosing patients. Coya CEO Arun Swaminathan said in a letter to investors that the company also plans to advance its clinical programs for the drug for FTD therapy in 2026.

Coya was founded in 2021. The company merged with Nicoya Health Inc. in 2020 and raised $10 million in its series A the same year. It closed its IPO in January 2023 for more than $15 million. Its therapeutics uses innovative work from Houston Methodist's Dr. Stanley H. Appel.

Houston-based Avance Biosciences' new Next-Generation Sequencing Center of Excellence will pursue breakthroughs in biologics, cell therapy and gene therapy. Photo via Getty Images.

Houston biosciences company opens new sequencing center for drug development

bioscience breakthroughs

Houston-based Avance Biosciences has launched the Next-Generation Sequencing Center of Excellence, designed to enhance the company’s sequencing capabilities for drug development. Specifically, the facility at the company’s main campus in Northwest Houston will pursue breakthroughs in biologics, cell therapy and gene therapy.

In the drug industry, sequencing refers to studying nucleotides in DNA and RNA molecules. Nucleotides are the building blocks of DNA and RNA.

“This is a major milestone for Avance Biosciences as we continue to support the evolving needs of biologics and cell and gene therapy developers,” Xuening “James” Huang, co-founder, CEO and chief technology officer of Avance, said in a news release. “By consolidating state-of-the-art sequencing platforms and scientific talent, we’ve created a highly capable organization ready to solve complex genomic challenges with precision and compliance.”

In 2013, Avance rolled out next-generation sequencing (NGS) that complies with federal guidelines. Since then, Avance “has remained at the forefront of regulated sequencing services,” the company said. “The launch of the (new center) strengthens the company’s ability to deliver accurate, reproducible, and regulatory-aligned sequencing data across a wide array of therapeutic modalities.”

Cal Froberg, senior vice president of sales and marketing at Avance, said pharmaceutical and biotech clients trust the company’s technical capabilities and regulatory compliance.

“With the ever-changing global landscape and increasing scrutiny around international sample shipments, conducting advanced, cost-effective NGS testing domestically is now more feasible than ever,” Froberg said. “Our clients have confidence that their samples will remain in the U.S.”

Avance, founded in 2010, plans to hold an open house at the new facility in September to showcase its capabilities, technology, talent, and services. The company’s services include sequencing, molecular biology, cell-based testing, and bioanalytical testing.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Intuitive Machines lands $600M satellite deal, NASA ‘spacecraft bus’ contract

space deals

Houston-based space infrastructure company Intuitive Machines has scored two astronomical deals.

The deals add to the company’s soaring success. As of June 30, Intuitive Machines had a record-high $1.8 billion backlog of orders, a $1.5 billion increase from the end of last year. The current backlog includes orders for more than 80 spacecraft.

The company, which went public in 2023, expects this year’s revenue to total $900 million to $1 billion. In the first half of 2026, Intuitive Machines generated nearly $393 million in revenue.

Intuitive Machines estimates its total available market is valued at more than $150 billion.

$600 million-plus deal represents ‘important milestone’

On Monday, Intuitive Machines said it picked up a $600 million-plus deal to develop three commercial satellites for an undisclosed customer over the course of about two years.

Intuitive Machines says it will design, manufacture, set up and support several spacecraft “for a critical communications infrastructure mission.”

Steve Altemus, the company’s CEO, says the deal represents “an important milestone for Intuitive Machines and reflects the confidence our customers place in our ability to deliver high-performance spacecraft for a broad range of mission needs.”

Company nails down NASA deal for ‘spacecraft bus’

A day after announcing the $600 million-plus deal, Intuitive Machines said it secured a new contract with NASA.

Intuitive Machines says NASA’s Jet Propulsion Laboratory in Southern California will use the company’s IM 300 “spacecraft bus” for an EAGLE-VSWIR Earth observation mission. The mission is scheduled to launch in 2028.

Aside from supplying the IM 300 bus, Intuitive Machines will carry out mission support services.

The low-Earth-orbit mission will be equipped with Intuitive Machines’ hyperspectral visible to shortwave infrared (VSWIR) instrument. This technology sees colors and details that aren’t visible to the human eye.

The instrument is “designed to perform surface biology and geology observations from Earth orbit while demonstrating technologies that could support future lunar and Mars exploration missions,” Intuitive Machines says.

Intuitive Machines builds mission-critical spacecraft, systems, and infrastructure for business and government customers. To date, the company has produced more than 300 spacecraft, delivered over 575 pounds of payload to the moon and launched about 100 satellites.

9 Houston-based companies make Fortune Global 500 list in 2026

Worldwide Rankings

Nine Houston companies landed on the 2026 Fortune Global 500 list, which ranks the world's largest corporations by revenue for the 2025 fiscal year.

Houston's showing on the list was led by energy companies, with Spring’s ExxonMobil claiming the top local spot. Here’s what Houston-area companies made the list, and where they ranked:

  • No. 15 ExxonMobil
  • No. 36 Chevron
  • No. 61 Phillip 66
  • No. 159 Sysco
  • No. 243 ConocoPhillips
  • No. 292 Enterprise Products Partners
  • No. 343 Plains GP Holdings
  • No. 460 SLB
  • No. 481 Hewlett Packard Enterprise

After 12 years as No.1, Arkansas-based Walmart was replaced this year by Seattle-based Amazon in the top spot for 2026. Amazon achieved this by bringing in $700 billion in revenue in 2025, representing a 12 percent increase from the previous year.

"Across global business, we see again and again that the leaders who are winning are those who embrace change,” Alyson Shontell, Fortune's editor in chief and chief content officer, said in a news release. "Amazon has topped the Fortune Global 500, knocking Walmart off its pedestal. The company has continually reinvented itself across new businesses and bold bets—including a $200 billion capital commitment, largely to building its capacity for AI and cloud computing, in this year alone."

The U.S. has 141 companies on the 2026 Fortune Global 500 list, which is the most of any country. Companies in America generated $15.5 trillion in aggregate revenues, a 6 percent increase from the previous year.

The number of women CEOs at Fortune Global 500 companies reached a record of 34 top leaders, who represented 6.8 percent of CEOs of companies on the list.

Technology was the standout growth industry on this year’s list, with 38 companies earning revenues that grew 20 percent to about $4 trillion in 2025, with profits climbing 36 percent to $835 billion. The financial sector accounted for the largest share of companies on the list again, with 123 companies in that sector. The energy sector claimed the No. 2 industry spot with 77 companies making the list.

In June, the Fortune 500 list was released, and Texas led the United States with 57 Fortune 500 companies headquartered in the state, generating $2.8 trillion in combined revenue.

Fast-growing Houston real estate startup surges to No. 7 on Inc. 5000

growth report

Houston-based Epique Realty has ridden the AI wave to rank among the Inc. 5000’s 10 fastest-growing private companies.

With three-year revenue growth of 23,210 percent, the AI-powered real estate brokerage appears at No. 7 on this year’s Inc. 5000 list. The 2026 list ranks private companies based on percentage revenue growth from 2022 to 2025.

Epique, founded in 2021, also ranks as the No. 1 fastest-growing company in Houston, No. 1 fastest-growing real estate company in the U.S., and No. 2 fastest-growing company in Texas.

Epique’s annual revenue surpasses $91 million

Between 2022 and 2025, the company’s annual revenue skyrocketed from $391,654 to more than $91.2 million. In 2025, the brokerage closed more than 23,000 deals and surpassed $7 billion in total sales, elevating Epique to the country’s 14th-largest real estate brokerage as measured by volume.

Epique’s network has more than 4,000 agents.

“To debut in the top 10 of the Inc. 5000 is absolute proof that when you relentlessly put agents first, exponential growth takes care of itself,” co-founder and CEO Joshua Miller said in a news release.

“We didn’t achieve this by following the industry playbook; we achieved this by burning it,” Miller added. “By fully funding our agents’ success through free health care, proprietary AI, and world-class leads, we’ve built a company where agents can finally thrive.”

The company’s other co-founders are Chris Miller, chief operating officer and vice president of expansion, and Janice Delci, chief financial officer.

Epique expands business to Canada, Mexico, Australia

The Millers and Delci have guided the company’s rapid expansion.

“Scaling our corporate support team to match [our] hyper-growth while seamlessly expanding across all 50 states and internationally to Canada, Australia, and Mexico takes an incomparable operational infrastructure,” Miller said.

“We have built an enterprise-grade technology ecosystem that allows us to absorb overhead and empower our agents at lightning speed,” he added. “This ranking validates that our disruptive model is working, and it is completely redefining the global industry standard.”

Epique launched its platform in 2023, touting itself as the industry’s first AI-powered brokerage. The startup’s platform provides AI tools for real estate agents to improve their marketing, streamline content creation, and boost engagement with clients and prospects.

Among Epique’s AI tools are:

  • ChatGPT for generation of property descriptions
  • AI-assisted creation of blog posts and agents’ bios
  • Production of Instagram quotes for social media marketing

“When we started Epique, we wanted to build a company that genuinely cared for its agents’ financial and physical well-being,” Delci says. “To see that vision translate into this level of historic record-breaking growth is a beautiful testament to the true power of radical generosity.”

Epique and fellow honorees will be recognized Oct. 14-16 at the 2026 Inc. 5000 Conference & Gala in Dallas.

Six other Houston-area companies land in top 250

Here are the six other Houston-area companies that claimed spots in the top 250 on the Inc. 5000 list. Each company name is followed by its ranking, headquarters city, and three-year growth rate.

  • No. 27 Empact Technologies, 8,275 percent
  • No. 60 Action1, 4,512 percent
  • No 75 Signs By G, 3,684 percent
  • No. 79 The ’Pause Life, 3,469 percent (Galveston)
  • No. 110 Turtlebox Audio, 2,576 percent
  • No. 178 Dahnani Private Equity Group, 1,904 percent (Stafford)

How did companies in Texas’ other major metros fare?

Here’s a breakdown of companies in the Austin, Dallas-Fort Worth, and San Antonio areas that made the top 250 on the Inc. 5000. Again, each company name is followed by its ranking, headquarters city, and three-year growth rate.

Austin (10 companies)

  • No. 9 Investment Watches, 15,741 percent
  • No. 72 Razor Metrics, 3,856 percent
  • No. 91 Autonomize AI, 2,921 percent
  • No. 102 Choose Your Horizon, 2,719 percent
  • No. 132 Wander Staffing, 2,296 percent
  • No. 144 Everyday Dose, 2,179 percent
  • No. 148 NetRise, 2,118 percent
  • No. 163 Nutrabound Labs, 1,999 percent (Bastrop)
  • No. 179 Steadily, 1,890 percent
  • No. 208 Tiny Health, 1,624 percent

Dallas-Fort Worth (11 companies)

  • No. 3 Yantran, 258,740 percent (Allen)
  • No. 12 Paek Management Group, 12,520 percent (Irving)
  • No. 82 Elite Robotics and Automation, 3,334 percent (Fort Worth)
  • No. 133 Outamation, 2,291 percent (Southlake)
  • No. 147 Red Creek Solutions, 2,119 percent (Frisco)
  • No. 155 JobTread Software, 2,071 percent (Dallas)
  • No. 164 DAX Eyewear, 1,977 percent (Nevada)
  • No. 186 Optimized Waste Removal, 1,830 percent (Fort Worth)
  • No. 204 Freight Flex, 1,642 percent (Denton)
  • No. 212 Maverick Power, 1,591 percent (McKinney)
  • No. 229 Innovative Life Sciences, 1,494 percent (McKinney)

San Antonio (one company)

  • No. 118 Hire With Near, 2,421 percent
View All Listings